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Malignant melanoma is one of the most rapidly grow-
ing neoplasms that develop during pregnancy. Tradition-
ally, it has been stated that women who are pregnant at 
the time of diagnosis have a poorer prognosis than wom-
en who are not pregnant. Additionally, the subsequent 
pregnancies were believed to increase the recurrence 
rate. There are very few studies in this area, but some 
authors of retrospective studies show that gestating 
women have poorer prognosis than non-pregnant wom-
en. Other authors report the presence of sex-hormone 
receptors in the melanoma tissue, suggesting a hormo-
nal sensitivity of this neoplasm. There is also a group of 
studies that do not confirm these findings.
A 32-year-old healthy patient reported to the Gy-
naecology Clinic, Jagiellonian University Medical College 
(JUMC) in her twenty-first week of gestation with a ver-
rucous lesion on the back in the interscapular area. The 
patient was consulted at the Outpatient Clinic of the De-
partment of Dermatology, JUMC. A melanocytic nevus, 
often irritated by the patient, was described. There were 
neither clinical nor dermoscopic features of an under-
lying neoplastic process, so photo-documentation was 
not performed at that time. The patient did not report 
any other illnesses or symptoms, and she did not take 
any medication. The pregnancy was endangered, so the 
patient decided to postpone the surgical excision of the 
lesion after giving birth. Five months later, the patient 
returned to the Clinic with a noticeably enlarged (now 3 × 
2 cm), polypous, ulcerated tumour. An excisional biopsy 
of the lesion was made – with a macroscopic margin of 
10 mm. The patient received chloramphenicol ointment, 
and dressings were applied. Histologically, the lesion was 
described as malignant melanoma, nodular type with 
ulceration. The neoplasm was in the vertical phase of 
growth, Clarke V, Breslow IV with mitotic activity of 14 mi-
totic figures/mm2. Features of vascular invasion were ob-
served on the basis of the lesion. In the dermis and sub-
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cutaneous area, numerous microsatellite foci were found, 
with the greatest being 2.2 mm in size. The lesion was re-
moved with microscopic borders of 1.2 mm and 4 mm lat-
erally and 6.5 mm deep. Abdominal ultrasound revealed 
hypo- and hyperechoic lesions in the liver (max. size: 
47 × 29 × 36 mm) and hypoechoic lesions in the spleen 
with a single enlarged lymph node near the head of the 
pancreas (16 × 7 mm). Nuclear magnetic resonance (NMR) 
confirmed hypo- and isointense lesions in T1 with en-
hancement after contrast, the largest being 36 × 44 mm 
in segment V. Similar lesions were described in the 
spleen (max. 15 mm). The patient was tested for the 
BRAF mutation. A chest X-ray revealed no abnormalities.
Two weeks later the patient observed a nodular le-
sion located on the right side of her parietal scalp. Der-
moscopy of the lesion was performed (Figures 1 A, B). 
The patient also complained of nonspecific muscle and 
lower limb pain. She was consulted by a neurologist who 
recommended Mg and K supplementation.
Nuclear magnetic resonance of the head revealed 
numerous small foci consistent with metastatic lesions 
to the brain: in the right cerebellar hemisphere (3 mm), 
in the right and left temporal lobes (max. 3 mm in size) 
and in the left parietal lobe (2 and 6 mm). Additional 
metastases were discovered in the right humerus (the 
patient did not report any pain in the right arm), as well 
as the thoracic and lumbar vertebra. Ultrasound re-
vealed a lymph node package in the right axilla (69 × 
32 mm) and a single node in the right supraclavicular area 
(15 × 15 mm). Brain and bone radiation therapy were rec-
ommended. During hospitalization, the patient reported 
severe weakness, dizziness, dyspnoea and peripheral 
oedema. Laboratory tests revealed: monocytosis 12.5% 
(range: 4–11), eosinophilia 0.8% (range: 1–5), microcytic 
anaemia with red blood cell (RBC) 3.44 mln/µl (range: 37–
47), haemoglobin (Hb) 9.4 (range: 12–16), mean platelet 
volume (MPV) 7.9 fl (range: 8.8–12), red cell distribution 
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width (RDW) 15% (range: 11.5–14.5). The patient was ad-
ministered buprenorphine transdermal therapy, tramad-
ol, diazepam, dexamethasone, ketoprofen, omeprazole, 
estazolam, and diclofenac. One month after excision of 
the lesion, she received brain radiotherapy (6 MV, 20 Gy). 
Unfortunately, disease progression was observed, with 
an increase in the liver parameters: alanine aminotrans-
ferase (ALT) 158 U/l (range: 5–31), aspartate transferase 
(AST) 223 U/l (range: 5–32), g-glutamyl transpeptidase 
(GGTP) 540 U/l (range: 6–42), low total protein 52.7 g/l 
(range: 64–83), hypoalbuminemia 27.6/24.3 g/l (range: 
34–48), hyperbilirubinemia 25.85 µmol/l (< 21), C-reactive 
protein (CRP) was 97.25 mg/l (range: 0–5) and mild hy-
ponatremia and hypercalcemia were observed. 
Complete blood count (CBC) revealed white blood 
cells (WBC) of 23.34 × 103/mm3 (range: 4.3–10); pro-
gress of microcytic anaemia with RBC of 3.3/3.16 × 106/
mm3 (range: 4–5.2), Hb 8.9/8.6 g/dl, haematocrit (Hct) 
27/27%, mean corpuscular volume (MCV) 81.8. (83 × 103), 
mean cell haemoglobin (MCH) 27 pg (range: 28–34) and 
thrombocytopenia 136/93 × 103/mm3 (range: 150–350), 
platelet-crit (PCT) 0.5% (range: 0.2–0.4), leucocytosis 
24.9 thousand/µl (range: 4–10) and lymphocytosis 
6.9 thousand/µl (range: 1.00–3.50). Despite the blood 
transfusions and albumin infusions, the patient devel-
oped electrolyte imbalance followed by cardiopulmonary 
and renal insufficiency (creatinine level of 155.5 µmol/l, 
urea 31.76). These changes were the direct cause of 
death. Later, the results of the BRAF qualification studies 
showed that the patient was positive for a BRAF muta-
tion and, therefore, could have received treatment with 
drugs targeting the BRAF/MEK growth pathway. 
It is important to mention that laboratory tests for 
viruses performed between the sixth and eighth weeks 
of pregnancy were non-diagnostic. A HIV screen and hep-
atitis B surface antigen test were initially positive, with 
non-reactive anti-HCV. The subsequent laboratory tests 
had to be repeated several times, due to “lack of coher-
ence” in hepatitis B surface antigen results; anti-HCV 
was negative. Western blot did not confirm HIV infection. 
Blood testing done at the beginning of the 4th month of 
gestation excluded hepatitis B infection. In the fourth 
month of gestation, C-reactive protein reached 14.9 mg/l 
(range: 0–5), while the other results remained within 
their reference ranges throughout the pregnancy. Prena-
tal studies performed in the first trimester showed an in-
creased risk of aneuploidy due to enhanced nuchal trans-
lucency (21 trisomy risk – 1 : 29, 18 – 1 : 784, 13 – 1 : 4190), 
and the PAPP-A value was normal. Ultrasound of the foe-
tus revealed a shortened jaw, impaired gastric filling, and 
a dilated renal pelvis. Some malformations of the lower 
part of cerebellar vermis were also observed. Ultimately, 
the patient developed polyhydramnios, and the clinical 
pattern was consistent with esophageal atresia. A spon-
taneous delivery occurred at 37 weeks gestation. The 
child was born weighing 2910 g, received 10 points on 
the Apgar scale and was positive for esophageal atresia. 
Malignant melanoma is the major cause of death 
from neoplasms in women of child-bearing age [1]. The 
incidence in gestation ranges from 0.14 to 2.8 per 1000 
pregnancies, which accounts for approximately 8% of 
all malignancies arising during gestation. Various stud-
ies show that it is the first or the second most common 
neoplasm diagnosed during pregnancy [1, 2]. According 
to Lambe, 5.6% of neoplasms diagnosed in women of 
child-bearing age occurred concurrently with pregnancy 
or lactation. Furthermore, the incidence of melanoma is 
increasing among women aged 15–39 years [3]. 
Many immunological changes are observed during 
pregnancy. The innate immunity is downregulated fa-
vouring allograft tolerance. Murine models show that 
T cells become aware of foetal alloantigens during ges-
tation. The precise mechanism of this process remains 
unknown [4–7]. The total number of effector cells is 
altered with an increase in granulocytes and decrease 
in lymphocytes. T-lymphocytes show impaired interleu-
kin-2 (IL-2) and interferon g (IFN-g) production after stim-
ulation. These processes clinically manifest as frequent 
Figure 1 A, B. Dermoscopic images of metastatic melanoma on the right side of the crown of the head
A B
Postępy Dermatologii i Alergologii 6, December / 2015
Melanoma in pregnancy: a case report and review of the literature 
485
remission of psoriasis and autoimmune diseases, such as 
rheumatoid arthritis and multiple sclerosis. Taking these 
changes into consideration, pregnancy was considered 
an aggravating factor of melanoma [8].
In the early 1950s, Pack and Scharnagel reported 
poor outcomes in 32 women with melanoma diagnosed 
during pregnancy. The authors recommended avoiding 
pregnancy for 3 to 5 years after completion of treatment 
[9]. Byrd and McGanity even postulated that female mel-
anoma patients should be surgically sterilized [10]. In 
1981, Houghton et al. compared 12 pregnant women with 
melanoma to 175 non-pregnant controls. After 5 years of 
follow-up there was no significant difference in survival 
between pregnant and non-pregnant women (55% vs. 
58 %). However, pregnant patients had prognostically poor-
er primary sites of melanoma and more advanced stage 
of the neoplasm [11]. Studies from the late 1980s through 
the early 1990s compared large numbers of pregnant and 
non-pregnant patients and demonstrated thicker melano-
ma tumours in the pregnant group compared to controls. 
The authors attributed the results to delayed diagnosis 
in pregnant women [12]. Few studies from this period re-
vealed a difference in survival between groups of pregnant 
and non-pregnant women with melanoma [13–15].
Khosrotehrani et al. showed that pregnancy results 
in increased lymphangiogenesis and subsequent me-
tastases in mice. Melanomas from pregnant mice had 
an increased expression of vascular endothelial growth 
factor A (VEGF A) at both the RNA and protein levels 
[16]. Nguyen-Huu et al. also postulated that tumours 
are thicker in pregnant women compared to controls 
[17]. Stoica et al. found that melanocytes have the abili-
ty to bind oestrogen and progesterone [18]. More recent 
studies on larger groups of patients with melanoma 
(450 post-pregnant women compared to 3000 non-preg-
nant individuals) demonstrated no difference in surviv-
al between the groups [19]. Miller et al. showed that 
pregnant women had more advanced disease than 
non-pregnant controls. The mean Breslow thickness was 
higher in the pregnancy group (4.28 mm) than in con-
trols (1.69 mm). This difference failed to reach statistical 
significance; most likely due to the small trial group. The 
number of melanoma-positive nodes, however, was sig-
nificantly higher. There was also a higher mortality rate 
(of borderline significance) in the pregnancy group com-
pared to the control groups [20, 21]. These results are in 
line with Reintgen’s study of 1985 [22, 23]. 
A few in vitro trials have revealed the presence of pro-
gesterone and oestrogen receptors on melanoma cells 
[24–26]. On the contrary, Morvillo et al. reported a lack 
of progesterone and oestrogen receptors, but instead 
found evidence that their melanoma cell lines were pos-
itive for androgen receptors. They demonstrated that 
testosterone, oestrogen and progesterone significantly 
stimulated melanoma cell proliferation [27]. Another in 
vitro study revealed that oestrogen and dihydrotestos-
terone changed nuclear morphology in melanoma cells. 
Kanda and Watanabe, on the other hand, reported that 
melanoma cell lines containing hormone receptors were 
down-regulated by 17β-oestradiol, progesterone, and 
testosterone. Cell lines without those receptors were not 
influenced by the sex hormones [28]. Miller et al. found 
a limited number of oestrogen receptors in melanoma 
tissue (2 positive out of 69 melanoma specimens) [29]. 
Melanoma tissue was also found positive for luteinizing 
hormone releasing hormone (LHRH) receptors – the cell 
line showed inhibited proliferation and reduced meta-
static activity in response to an LHRH receptor agonist 
[30]. Some epidemiologic studies report that the mela-
noma risk decreases with higher parity and has a ten-
dency to increase in individuals who delayed their first 
pregnancy. A French prospective study suggests that the 
risk of melanoma is reduced with decreased exposure to 
ovarian hormones [31–33]. A study conducted by Eller-
horst et al. shows that melanoma cells proliferate in re-
sponse to TRH and TSH, but also indicates that leptin 
may play the role of melanoma growth factor [34, 35]. In 
their study, melanoma cells strongly expressed the lep-
tin receptor, whereas nevi had less receptor expression. 
Since leptin regulates many processes during gestation, 
interacts with gestation-specific serum-borne factors and 
steroid receptors, and it is linked to preeclampsia, gesta-
tional diabetes and intrauterine growth restriction, it can 
be assumed that pregnancy and melanoma may affect 
each other [36].
Melanoma is one of few neoplasms (including leu-
kemias, lymphomas, lung and breast cancer) that has 
the potential to metastasize to the placenta. In fact, it 
is the most common neoplasm involving the foetus and 
placenta (approximately 31% of all neoplasms). The risk 
of metastasis to the placenta and foetus is low and oc-
curs in patients with widely metastatic melanoma [37]. 
Metastases have a predilection to male new-borns (80% 
of children with melanoma metastases). Since the first 
report in 1866 until 2003 only 87 cases of placental or 
foetal metastasis were reported. Many authors suspect 
that placentas from pregnancies where the mother had 
MM were not always examined microscopically or that 
follow-up of children derived from these pregnancies was 
too short [37]. 
Hormone replacement therapy (HRT) and contracep-
tion do not seem to be risk factors for melanoma devel-
opment. MacKie et al. reported that the use of HRT after 
treatment for stage 1 melanoma did not have adverse 
effects on patients’ outcomes [14]. Likewise, Tang et al. 
showed that menopausal hormone therapy did not af-
fect the overall incidence of melanoma or non-melanoma 
skin neoplasms in postmenopausal patients [38].
Since most melanoma recurrences happen within 
2 years after surgical excision of the neoplasm, several au-
thors suggest delaying pregnancy for 2–3 (or even 5) years 
after completion of treatment. The exact time depends on 
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the tumour thickness, presence of ulceration, and senti-
nel node metastasis [39]. The treatment options are sim-
ilar in pregnant and non-pregnant individuals. Patients 
with superficial lesions require excision with wide sur-
gical margins under local anaesthesia, followed by close 
clinical monitoring. Studies show that excisional biopsy 
under local anaesthesia poses a very low risk either to the 
mother or foetus. Furthermore, sentinel node biopsy with 
dye and lymphoscintigraphy is not contraindicated during 
pregnancy. Some authors, however, recommend avoiding 
lymphoscintigraphy before the 30th week of gestation and 
postponing sentinel node biopsy until delivery [40]. 
Melanoma is a rapidly growing neoplasm that can 
rarely metastasise to the placenta and the foetus if it 
occurs during pregnancy. Early reports suggested a rapid 
progression of the disease during pregnancy, but more 
recent data do not support this statement. In our case, 
we observed dynamic progression of the disease, which 
coincides with the early case reports. Caring for an ex-
pecting mother with melanoma is emotionally difficult 
and challenging for every provider. This is probably the 
reason why cases of melanoma occurring during preg-
nancy are described so often in the literature. Unfortu-
nately, our patient’s child was born with several malfor-
mations. Of note, there have been no studies implicating 
melanoma as a trigger or risk factor for developmental 
abnormalities. The most recent studies show that the 
prognosis of melanoma during pregnancy is similar to 
that of non-pregnant women. Despite this fact, follow-up 
examinations of pigmented skin lesions should be per-
formed with care, and other risk factors for malignant 
melanoma should be explored [41]. Additionally, the pla-
centas of women with suspected or known disseminated 
disease should be examined carefully. 
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